Bio2Bedside Podcast live at Advanced Therapies Week - Leading Responsibly in Right-To-Try Legislation

Last year, Montana passed Senate Bill 535. Clinics can now offer experimental treatments that have completed Phase I trials but haven't yet received FDA approval. 

It's the most expansive legislation of its kind in the country. 

For years, the conversation around right-to-try has been driven by longevity researchers and VCs. People who want to inject themselves with experimental therapies and are willing to pay for the privilege, but that’s not the only group this legislation should support.  

This session will discuss how to lead responsibly from the front in using this legislation for rare diseases. 

If the rare disease community doesn't show up to shape this conversation, someone else will.  
And their priorities may not be ours.